Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Croton membranaceus hydroethanolic root extract (CMERE) is a botanical extract derived from the roots of *Croton membranaceus*, a plant indigenous to West Africa, particularly Ghana, where it is traditionally used to treat prostate-related conditions. CMERE functions as an antiangiogenic agent, demonstrating the ability to suppress the expression of platelet-derived growth factor receptor beta (PDGFRβ) and reduce microvessel density in tumor models. Preclinical research indicates that it inhibits the formation of new blood vessels, disrupts vascular tree structures, and decreases microcirculatory routes, thereby limiting the nutrient supply necessary for the progression and metastasis of prostate adenocarcinoma. It is primarily investigated for its potential in managing benign prostatic hyperplasia (BPH) and prostate cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on croton membranaceus hydroethanolic root extract.